-- that Selzentry along with an optimized background regimen significantly
increased CD4 cells as compared to patients receiving optimized
background regimen alone, and
-- that patients receiving Selzentry experienced similar adverse events to
those receiving an optimized regimen alone.
Monogram's phenotypic resistance tests were used to optimize background therapy in Selzentry's clinical trials.
Selzentry is designed to work differently from other available HIV medications. CCR5 antagonists block the virus from gaining access into healthy cells via the CCR5 co-receptor, a common pathway for viral entry. Monogram's Trofile co-receptor tropism assay identifies whether individual strains of HIV use the CCR5 co-receptor, the CXCR4 co-receptor or both co- receptors to infect healthy cells. This helps clinicians determine whether a CCR5 antagonist like maraviroc may be a good therapeutic option for treating individual patients. Currently available in the U.S., Selzentry is the first drug in a new oral class of HIV medications to be approved in more than ten years. Selzentry (Maraviroc) is under review with European regulatory authorities and recently received a positive opinion from the CHMP.
Selzentry and other entry inhibitors currently in development come at a time when increasing drug resistance makes treating HIV more difficult than ever. Highly sensitive and precise diagnostic tools, such as Trofile, are playing an ever more important role in the development of new therapeutic approaches that give new hope to physicians and patients running low on options.
Trofile is a patient selection co-receptor tropism assay that
determines which co-receptor a patient's HIV strain or strains use for
viral entry- CCR5, CXCR4, or a combination of CCR5 and CXCR4. Which of
these "cellular gateways" that a particular HIV strain uses to gain entry
|SOURCE Monogram Biosciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved